Amgen announced its exit from neurology research as sales slumped in its third quarter, while higher net income and stock buybacks propelled earnings per share up 14 percent. Despite the initial success of its migraine treatment Aimovig, the Thousand Oaks biotech giant announced its intention to call off early forays into neuroscience research, shifting its…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
